Treatment for lung cancer that has spread to the chest wall
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment for a type of lung cancer that has grown into the chest wall or nearby blood vessels. It combines radiation therapy, the immunotherapy drug durvalumab, and surgery, and researchers want to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that is growing into the chest wall or a major blood vessel in the top of the chest.
- The cancer cannot have spread to distant parts of the body.
- You must be able to have the affected lung lobe removed safely.
- You must be between 20 and 75 years old.
- You must be in good general health (able to do your daily activities) and have adequate lung function.
- You must not have had previous chemotherapy or major chest surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach: giving an immunotherapy drug (tislelizumab) plus chemotherapy before surgery or radiation for advanced lung cancer that has spread to chest lymph nodes. The goal is to shrink the cancer first, then remove or treat it, to improve chances of long-term control.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
This trial tests a new combination of radiation therapy, an immunotherapy drug (tislelizumab), and chemotherapy to shrink bulky stage III lung cancer before possible surgery. The goal is to see if this approach is safe and effective.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.